Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Office of Research & Development

print icon sign up for VA Research updates

Funded Project Details - FY2021




Project Number:

I01CX002006-01
Title: A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
Principal Investigator:

Matthew B. Rettig

Location: West Los Angeles, CA
Congressional District Code: 33
Research Service: Clinical Science R&D
Project Period: April 2020 - March 2024
FY 2021 Funding Amount: $1,053,290
Total Award Amount
(all years):
$2,482,756
Abstract: View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER


Excerpt:

Alternative treatment approaches are urgently needed to improve quantity and quality of life of patients with metastatic castration resistant prostate cancer (mCRPC). Immunotherapy in the form of checkpoint inhibition has yielded auspicious results in many cancers, including lung cancer, melanoma, renal cell carcinoma, and lymphoma amongst several others. The frequency of tumor-specific somatic mutations and hence neoantigen formation strongly predicts for objective response to checkpoint inhibi...



Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.